<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01994772</url>
  </required_header>
  <id_info>
    <org_study_id>RCB 2012-A00405-38</org_study_id>
    <nct_id>NCT01994772</nct_id>
  </id_info>
  <brief_title>Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm</brief_title>
  <acronym>HYPERION</acronym>
  <official_title>Therapeutic Hypothermia After Cardiac Arrest in Non Shockable Rhythm at Rescue Arrival: The HYPERION Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Departemental Vendee</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Departemental Vendee</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac arrest is at present a major cause of mortality as well as a cause of disability for
      the surviving victims.In Europe, every year counts as 300,000 cardiac arrests responsible for
      250,000 deaths. Thus, less than 20 % of patients discharged home with impaired quality of
      life associated with symptoms of tiredness, stress, anxiety. The prognosis is related to the
      initial cardiac rhythm present during the initiation of resuscitation. Recent progress in the
      improvement of mortality and neurological outcome has been achieved over the last decade
      thanks to the systematic implementation of a period of targeted temperature control between
      32 and 34 ° C in patients who benefited from the realization of at least one electrical
      external shock.

      There are theoretical and clinical arguments to think that achieving the same way a period of
      targeted temperature control between 32 and 34 ° C in patients treated for cardiac arrest
      with a non- shockable rhythm on arrival can also benefit from this procedure. However other
      arguments are against this hypothesis including an increase in the risk of infection ,
      worsening of the patient's hemodynamic status with no benefit to him. To answer this
      question, we conduce a randomized multicenter study testing the potential improvement of
      neurological outcome through this procedure targeted temperature control between 32.5 and
      33.5 ° C in these patients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2014</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Neurological outcome assessed with Cerebral Performance Category scale</measure>
    <time_frame>Day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit Mortality</measure>
    <time_frame>Discharge from Intensive Care Unit, an expected average of 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Mortality</measure>
    <time_frame>Discharge from hospital, an expected average of 2 weeks</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality at day 90</measure>
    <time_frame>Day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Day 90</time_frame>
    <description>Quality of life at day 90 will be assessed by 36-Items Short Form for Health Survey telephonic interview</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life autonomy</measure>
    <time_frame>Day 90</time_frame>
    <description>Life autonomy will be assessed by Index Activity of Daily Living, modified Barthel index, and by two normative question about life autonomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neurocognitive evaluation</measure>
    <time_frame>Day 90</time_frame>
    <description>Neurocognitive status will be assessed by telephonic validated version of Mini Mental State Examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post traumatic stress disorders symptoms</measure>
    <time_frame>Day 90</time_frame>
    <description>Post traumatic stress disorders symptoms will be assessed by Impact Event Scale Revised</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit length of stay</measure>
    <time_frame>Discharge from Intensive Care Unit, an expected average of 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>Discharge from hospital, an expected average of 2 weeks</time_frame>
    <description>Participants will be followed for the duration of hospital stay, an expected average of 2 weeks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation duration</measure>
    <time_frame>Time from extubation, an expected average of 4 days</time_frame>
    <description>Participants will be followed for the duration of mechanical ventilation, an expected average of 4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hemorrhage</measure>
    <time_frame>Intensive care unit length of stay, an expected average of 7 days</time_frame>
    <description>Severe hemorrhage is define by transfusion of 1 or more blood product requirement and/or intracranial hemorrhage. Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial Bloodstream infection</measure>
    <time_frame>Intensive care unit length of stay, an expected average of 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early onset pneumonia</measure>
    <time_frame>2 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilated Associated Pneumonia</measure>
    <time_frame>Duration of mechanical ventilation, an expected average of 4 days</time_frame>
    <description>Participants will be followed for the duration of mechanical ventilation, an expected average of 4 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Veinous Catheter infection</measure>
    <time_frame>Intensive care unit length of stay, an expected average of 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of inotropic drugs</measure>
    <time_frame>48 hours</time_frame>
    <description>Total dose of different inotropic drugs (Epinephrine, Norepinephrine, Dobutamine) will be compare between 2 groups during targetted controlled temperature management period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Extra renal support requirement</measure>
    <time_frame>Intensive care unit length of stay, an expected 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute pulmonary oedema by left ventricular failure</measure>
    <time_frame>Intensive care length of stay, an expected 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure</measure>
    <time_frame>Intensive care length of stay, an expected 7 days</time_frame>
    <description>Participants will be followed for the duration of Intensive care unit stay, an expected average of 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe arrythmia</measure>
    <time_frame>Intensive care unit length of stay, an expected 7 days</time_frame>
    <description>Severe arrythmia will be define by salvo of ventricular extrasystole, ventricular fibrillation, ventricular tachycardia, need an external shock, need anti-arrhythmic treatment. Participants will be followed for the duration of Intensive Care Unit stay, an expected average of 7 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">584</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Targeted controlled temperature between 32.5 and 33.5°C</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will be placed in targeted temperature control between 32.5 and 33.5 ° C for 24 hours and then slowly rewarmed for targeted temperature control between 36.5 and 37.5 ° C for 24 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Targeted controlled temperature between 36.5 and 37.5°C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will be placed in targeted temperature control between 36.5 and 37.5 ° C for 48 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted controlled temperature between 32.5 and 33.5°C</intervention_name>
    <description>Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.</description>
    <arm_group_label>Targeted controlled temperature between 32.5 and 33.5°C</arm_group_label>
    <other_name>Therapeutic hypothermia</other_name>
    <other_name>Induce hypothermia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Targeted controlled temperature between 36.5 and 37.5°C</intervention_name>
    <description>Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.</description>
    <arm_group_label>Targeted controlled temperature between 32.5 and 33.5°C</arm_group_label>
    <arm_group_label>Targeted controlled temperature between 36.5 and 37.5°C</arm_group_label>
    <other_name>Normothermia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cardiac arrest in non shockable rhythm

          -  Glasgow score ≤ 8

        Exclusion Criteria:

          -  No flow &gt; 10 min

          -  Low flow &gt; 60 min

          -  Major hemodynamic instability

          -  Delay between cardiac arrest and inclusion &gt; 300 min

          -  Cirrhosis Child C

          -  Age &lt; 18 years

          -  Pregnant women

          -  Patient with no liberty

          -  Lack of informed consent

          -  Prior inclusion in a research protocol involving cardiac arrest with draw, and whose
             primary endpoint focuses on the evaluation of a neurological score Day 90
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean Baptiste Lascarrou, MD</last_name>
    <role>Study Chair</role>
    <affiliation>CHU Nantes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean Baptiste Lascarrou, MD</last_name>
    <phone>+33251446212</phone>
    <email>jeanbaptiste.lascarrou@chu-nantes.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Martin, MD</last_name>
    <phone>+33251446483</phone>
    <email>stephanie.martin@chd-vendee.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Asfar, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Angouleme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Christophe Cracco, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michel Sirodot, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Argenteuil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gaetan Plantefeve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisabeth Coupez, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Quenot, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>La Roche Sur Yon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenhael Colin, MD</last_name>
      <email>gwenhael.colin@chd-vendee.fr</email>
    </contact>
    <investigator>
      <last_name>Jean Baptiste Lascarrou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Le Mans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mickael Landais, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Lens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Didier Thevenin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Girardie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nicolas Pichon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Lorient</city>
        <zip>56322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Guillaume Grillet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Montauban</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Frederic Bellec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-Baptiste Lascarrou, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Orleans</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Thierry Boulain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cochin University Hospital Center</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alain Cariou, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Frat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Roanne</city>
        <zip>42300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jean-Charles Chakarian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Rodez</city>
        <zip>12000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Arnaud Delahaye, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Saint Brieuc</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Julien Letheulle, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Saint Malo</city>
        <zip>35400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Vlad Botoc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Saint Nazaire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ferhat Meziani, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Intensive Care Unit</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre Francois Dequin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Surgical Intensive Care Unit</name>
      <address>
        <city>Versailles</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Stephane Legriel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Pointe à Pitre</name>
      <address>
        <city>Pointe-à-Pitre</city>
        <zip>97120</zip>
        <country>Guadeloupe</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Khalid Elkoun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Guadeloupe</country>
  </location_countries>
  <link>
    <url>http://www.sjtrem.com/content/23/1/26</url>
  </link>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 7, 2013</study_first_submitted>
  <study_first_submitted_qc>November 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2013</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic hypothermia</keyword>
  <keyword>Targeted controlled temperature</keyword>
  <keyword>Cardiac arrest</keyword>
  <keyword>Non shockable rhythm</keyword>
  <keyword>successful resuscitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

